Comunicati Stampa
Salute e Benessere

Bioretec Appoints Jordy Winters as Vice President of OUS Sales to Accelerate International Growth

Sarah van Hellenberg Hubar-Fisher, CEO of Bioretec, states: "We are delighted to welcome Jordy Winters to our executive team. With nearly two decades of proven excellence in global orthopedic commercial leadership, his expertise and international perspective will be instrumental as we continue to expand Bioretec's impact outside the U.S." Sarah van Hellenberg Hubar-Fisher, CEO of Bioretec, states:"We are delighted to welcomeJordy Wintersto our executive team. With nearly two decades of...
TAMPERE, Finland, (informazione.news - comunicati stampa - salute e benessere)

Sarah van Hellenberg Hubar-Fisher , CEO of Bioretec, states:

 said Jordy Winters .

In parallel, , previously Vice President of OUS Sales, will transition into the newly created role of . In this position, Ojala will lead efforts to advance surgeon training programs, develop educational initiatives, and support clinical adoption of Bioretec's pioneering technologies worldwide.

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.

Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA polymer. These implants deliver secure fixation through patented innovations and naturally degrade in approximately two years, eliminating the need for costly and invasive removal surgeries while supporting optimal bone regeneration. Activa products are both CE marked, and FDA cleared for a wide range of indications in adult and pediatric patients.

The company's latest innovation, the RemeOs  product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023 , and in Europe , the CE mark approval was received in January 2025 . With the development of next-generation implants like RemeOs, Bioretec is shaping the future of orthopedic treatment, paving the way for more effective and patient-friendly solutions.

To learn more about Bioretec, visit https://bioretec.com.

Megan Pino
Megan.pino@bioretec.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioretec/r/bioretec-appoints-jordy-winters-as-vice-president-of-ous-sales-to-accelerate-international-growth,c4228265

 

View original content:https://www.prnewswire.co.uk/news-releases/bioretec-appoints-jordy-winters-as-vice-president-of-ous-sales-to-accelerate-international-growth-302543874.html

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Non disponibili